PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Oteracil→

Oteracil PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
937-13-3
Molecular formula
C4H3N3O4
Molecular weight
157.08 g/mol
Drug class
Orotate phosphoribosyltransferase (OPRT) inhibitorfluoropyrimidine-modulating component
Mechanism of action
Oteracil potassium preferentially localises in gastrointestinal tissues and inhibits orotate phosphoribosyltransferase, reducing conversion of 5-fluorouracil to active metabolites in the gut and thereby reducing gastrointestinal toxicity when used in the tegafur/gimeracil/oteracil (S-1) combination.
Indications / reported uses
  • Used only as a component of the fixed-dose tegafur/gimeracil/oteracil combination (S-1/Teysuno) for selected solid tumours; oteracil alone is not a stand-alone antineoplastic treatment.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-gimeracil-oteracil-potassium · https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno · https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Oteracil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Oteracil Permitted Daily Exposure (PDE) report (the Oteracil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Oteracil Occupational Exposure Limit (OEL) report (the Oteracil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.